S-209

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameS-209
Drug Alias NameFlt3/Flt4 inhibitors (Sentinel Oncology)S-209
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVascular endothelial growth factor receptor 3 antagonistsTyrosine-protein kinase receptor FLT3 inhibitors
TargetsTyrosine-protein kinase receptor FLT3Vascular endothelial growth factor receptor 3
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesSentinel Oncology Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSentinel Oncology Ltd
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A